Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)

Main Article Content

Karl Lewis
Division of Medical Oncology, University of Colorado Hospital, Aurora, CO, USA

Katty Peris
Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy

Aleksandar Sekulic
Department of Dermatology, Arizona Mayo Clinic, Scottsdale, AZ, USA

Alexander Stratigos
Department of Dermatology-Venereology, Andreas Sygros Hospital-National and Kapodistrian University of Athens, Athens, Greece

Lara Dunn
Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Zeynep Eroglu
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

Anne Lynn Chang
Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA

Michael Migden
Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Siyu Li
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Suk-Young Yoo
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA

Kosalai Mohan
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Ebony Coates
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Emmanuel Okoye
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Jean-Francois Baurain
University Catholic of Louvain, Brussels, Belgium

Oliver Bechter
Department of General Medical Oncology, University Hospitals, Leuven, Belgium

Axel Hauschild
Department of Dermatology, Schleswig-Holstein University Hospital, Kiel, Germany

Marcus Butler
Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

Leonel Hernandez-Aya
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA

Lisa Licitra
Medical Oncology Head and Neck Cancer Department, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy

Rogerio Neves
Penn State Cancer Institute, Hershey, PA, USA

Emily Ruiz
Department of Dermatology, Dana-Farber Cancer Institute, Boston, MA, USA

Frank Seebach
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Timothy Bowler
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Matthew Fury
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Keywords

Metastatic Basal Cell Carcinoma, mBCC, Biologic, Cemiplimab, Hedgehog Inhibitor, HHI

Abstract

Abstract not available.

References

1. Puig S et al. Clin Transl Oncol. 2015;17:497–503.

2. Wu S et al. Am J Epidemiol. 2013;178:890–897.

3. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

4. Murphy AJ et al. Proc Natl Acad Sci USA. 2014;111:5153–5158.

5. Macdonald LE et al. Proc Natl Acad Sci USA. 2014;111:5147–5152.

6. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

7. Sezer A et al. Poster presented at European Society of Medical Oncology (ESMO) Virtual Congress 2020. September 19–21, 2020: LBA52.

8. Migden MR et al. N Engl J Med. 2018;379:341–351.

9. Stratigos A et al. Poster presented at ESMO Virtual Congress 2020. September 19–21, 2020: LBA47.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.3

Article Details

How to Cite
[1]
Lewis, K., Peris, K., Sekulic, A., Stratigos, A., Dunn, L., Eroglu, Z., Chang, A.L., Migden, M., Li, S., Yoo, S.-Y., Mohan, K., Coates, E., Okoye, E., Baurain, J.-F., Bechter, O., Hauschild, A., Butler, M., Hernandez-Aya, L., Licitra, L., Neves, R., Ruiz, E., Seebach, F., Lowy, I., Bowler, T. and Fury, M. 2021. Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s3. DOI:https://doi.org/10.25251/skin.5.supp.3.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from WC21 Clinical Dermatology Conference®: Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 > >>